Sold as Nexium Iv. Every FDA application for this active ingredient: 1 branded and 8 generic.
As of Nov 16, 2026, FDA lists 9 applications for Esomeprazole Sodium (sold as Nexium Iv), first approved Mar 31, 2005, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Esomeprazole Sodium | Part D | $38K | +23% | 15 |
| The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter PyloriHELICOBACTER PYLORI INFECTIONS · Xuanzhu Biopharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | May 26, 2026 |
| Esomeprazole Plus Sucralfate for Post-ESD Ulcer HealingEarly Gastric Cancer, Gastric Dysplasia · LanZhou University | Phase 4 | Not yet recruiting | Dec 31, 2025 |
| Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer BleedingPeptic Ulcer Bleeding · Shandong New Time Pharmaceutical Co., LTD | Phase 2 | Not yet recruiting | Jan 20, 2025 |
| Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal BleedingUpper Gastrointestinal Hemorrhage · West China Hospital | Phase 4 | Not yet recruiting | Nov 22, 2022 |
| Mar 31, 2005 | Nexium IvNDA 21689 · New dosage form | Astrazeneca | 28 | Discontinued |
| Mar 18, 2013 | Esomeprazole SodiumANDA 200882 | Sun Pharm | 2 | Discontinued |
| Sep 25, 2015 | Esomeprazole SodiumANDA 205379 | Accord Hlthcare | 6 | Discontinued |
| Aug 10, 2016 | Esomeprazole SodiumANDA 204657 | Eugia Pharma | 7 | Discontinued |
| Mar 6, 2017 | Esomeprazole SodiumANDA 207181 | Regcon Holdings | 0 | Marketed |
| May 17, 2017 | Esomeprazole SodiumANDA 202686 | Pharmobedient | 5 | Discontinued |
| Apr 1, 2020 | Esomeprazole SodiumANDA 203349 | Gland | 2 | Marketed |
| Feb 10, 2022 | Esomeprazole SodiumANDA 215732 | Hainan Poly | 2 | Marketed |
| Jan 8, 2025 | Esomeprazole SodiumANDA 214046 | Epic Pharma LLC | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA